Bionectria

Bionectria: A Mycological Genus of Scientific Interest in Natural Products Research

Overview and Important Preliminary Note

Bionectria is a genus of filamentous ascomycete fungi that has attracted growing scientific attention as a source of structurally novel and biologically active secondary metabolites. It is important to establish at the outset that, as of the current literature, Bionectria does not occupy any established or documented role as a traditional herbal remedy or as a standardised dietary supplement ingredient. No government health authority (NIH, NCCIH, EMA, EFSA, WHO), no official pharmacopoeia, and no clinical-trial registry recognise Bionectria in a dietary supplement context, and no human or clinical trials examining Bionectria extracts for health outcomes have been published in peer-reviewed literature. Its scientific relevance lies entirely in preclinical natural products chemistry and laboratory bioactivity research, which is described in detail below.

Identity and Taxonomy

Classification

According to the GBIF Backbone Taxonomy, Bionectria belongs to the kingdom Fungi, phylum Ascomycota, class Sordariomycetes, order Hypocreales, and family Bionectriaceae. Bionectria ochroleuca — the most extensively studied species — is classified in the family Bionectriaceae.

The accepted scientific name for the most-studied species is Bionectria ochroleuca (Schwein.) Schroers & Samuels, formally published in 1997 in Z. Mykol. 63(2): 151.

Synonyms and Nomenclatural History

The genus and its key species carry a long list of older synonyms reflecting changes in mycological classification over more than a century. Synonyms include Calonectria equiseti Starbäck, 1905; Creonectria ochroleuca (Schwein.) Seaver; Cucurbitaria ochroleuca (Schwein.) Kuntze; Nectria gliocladioides Smalley & H.N. Hansen; Nectria ochroleuca (Schwein.) Berk.; and Nectria ochroleuca var. longispora Wollenw.

The relationship between Bionectria and its asexual (anamorphic) form is taxonomically important. The anamorph of Bionectria ochroleuca was classified in Clonostachys Corda as C. rosea (Link : Fr.) Schroers et al. (1999), which is equivalent to Penicillium roseum Link : Fr. and Gliocladium roseum Bain. The anamorph of Bionectria ochroleuca (Hypocreales) is morphologically indistinguishable from Clonostachys rosea; Bionectria is generically distinct from Nectria s.s. and is the appropriate genus for species of the Nectria ochroleuca group.

From a nomenclatural priority standpoint, Clonostachys is an asexual morph-typified genus that has priority over the sexual morph-typified genus Bionectria; the type species of Clonostachys is C. araucaria Corda 1839, now considered a synonym of C. rosea (Link) Schroers et al. 1999, itself the anamorph of B. ochroleuca (Schwein.) Schroers & Samuels 1997.

Infrageneric Diversity

Schroers (2001) classified 35 Bionectria species having the Clonostachys anamorph and 9 other Clonostachys taxa based on detailed morphological and molecular data; he also divided the genus Bionectria into six newly distinguished subgenera — Bionectria, Zebrinella, Astromata, Myronectria, Epiphloea, and Uniparietina — based on morphology of stroma, structure of perithecial wall, habit of the perithecia, ornamentation and septation of ascospores, and phylogenetic data.

Species of the genus Bionectria (Hypocreales, Bionectriaceae) with anamorphs in Clonostachys are reviewed as a distinct group; Bionectria is distinct from other genera of the Bionectriaceae in overall shape and septation of the ascospores, ascus morphology, life-style, and particularly in characters of the anamorph. Bionectria forms a monophyletic clade based on analyses of the partial large subunit of the ribosomal DNA (LSU rDNA), and besides other life-styles, species of Bionectria include destructive mycoparasites, of which some are used as biocontrol agents of fungal plant pathogens.

Holomorphic species of fifteen genera in the family Bionectriaceae, Hypocreales, and related anamorph species have been studied using nuclear large subunit rDNA sequences; most elements of the Bionectriaceae form a monophyletic group closely related to representatives of two other families in the Hypocreales, namely the Clavicipitaceae/Hypocreaceae, which is distinct from the Nectriaceae.

Ecological Lifestyle

The fungal genus Clonostachys (formerly named Gliocladium), teleomorph Bionectria (formerly named Nectria or Nectriopsis), belongs to the family Bionectriaceae of Sordariomycetes in Ascomycota; Clonostachys fungi are widely distributed all over the world and are saprotrophs, destructive mycoparasites, lichenicoles, or inhabitants of recently dead trees and decaying leaves.

Endophytic fungi of the genus Bionectria are a source of new natural products with great potential for medicinal and agricultural applications; mangrove plants live in tropical and subtropical forests and share the ability to grow in estuarine and coastal environments. Mangrove-derived endophytes are attracting significant attention due to their potential for producing novel metabolites.

Bionectria ochroleuca is also documented as a plant pathogen that causes seed rot in oilseed rape.

Natural Sources and Habitats

Species of Bionectria have been isolated from a diverse range of environmental niches. Key documented sources in the literature include:

• Bionectria ochroleuca has been isolated from the inner leaf tissues of the mangrove plant Sonneratia caseolaris (Sonneratiaceae) from Hainan Island, China.
• Bionectria ochroleuca NOTL33 was investigated as a foliar endophytic fungus from Nothapodytes foetida, a medium-sized tree known to produce the antineoplastic compound camptothecin; the fungal isolate was identified as Bionectria ochroleuca based on ITS rDNA analysis.
• Similar strains of endophytic Bionectria ochroleuca have been isolated from Macleaya cordata and Paris polyphylla var. chinensis.
• In a study from Las Yungas Pedemontana forest (Tucumán, Argentina), fibrinolytic enzyme production was evaluated in fungal specimens isolated from subtropical forest; proteolytic activity was positive in 62% of isolates screened, whilst only three were able to produce extracellular fibrinolytic enzymes on solid nutritive medium; fibrinolytic-positive extracts were able to degrade fibrin clots in a direct plasminogen-independent way; isolates LY 4.1 and LY 4.4 showed 99.9% similarity with Bionectria ochroleuca.
• The first bionectriol-type molecule, designated bionectriol A, was isolated from Bionectria sp. associated with the fungus-growing ant Apterostigma dentigerum.
• A soil-derived isolate of Bionectria ochroleuca (designated BVK-SMA-2) was obtained from a soil sample collected in Buffalo Valley, Oklahoma; BLAST analysis of its ITS sequence data demonstrated the isolate was 99% identical to B. ochroleuca.

Traditional and Historical Use

No documented traditional use of Bionectria species as medicinal preparations has been identified in the peer-reviewed mycological, ethnobotanical, or ethnopharmacological literature. Natural products of fungi belonging to the genus Bionectria were only rarely studied until recently. Unlike well-known medicinal fungi such as Ganoderma lucidum, Cordyceps sinensis, or Lentinus edodes — which have centuries-long records of use in East Asian traditional medicine — Bionectria species do not appear in any known traditional pharmacopoeia, materia medica, or ethnobotanical record. The scientific investigation of this genus has been essentially a product of late-twentieth and early twenty-first century natural products chemistry, driven by laboratory screening rather than traditional-use knowledge.

Key Constituents and Active Compounds

The chemistry of Bionectria (and its asexual counterpart Clonostachys) is remarkably diverse. Clonostachys (teleomorph: Bionectria) fungi are well known to produce a variety of secondary metabolites with various biological activities to show their pharmaceutical and agrochemical applications; at least 229 secondary metabolites have been reported, including 84 nitrogen-containing metabolites, 85 polyketides, 40 terpenoids, and 20 other metabolites, and many of these compounds exhibit cytotoxic, antimicrobial, antileishmanial, and antimalarial activities.

Cyclic Peptides and Depsipeptides (Pullularins)

Three cyclic hexadepsipeptides — pullularins A, C, and E — were isolated from the endophytic fungus Bionectria ochroleuca; both pullularins A and C showed moderate cytotoxic activity against mouse lymphoma cells. Chemical investigation of the ethyl acetate extract of B. ochroleuca, isolated from the inner leaf tissues of Sonneratia caseolaris from Hainan Island, China, yielded two new peptides, pullularins E and F, together with three known compounds; the structures of the new compounds were unambiguously determined on the basis of one- and two-dimensional NMR spectroscopy and by high-resolution mass spectrometry.

Epidithiodioxopiperazines (Bionectins)

Three new epidithiodioxopiperazine compounds — bionectins A, B, and C — together with a known compound, verticillin D, have been isolated from the mycelium of liquid fermentation cultures of the fungus Bionectra byssicola F120; compounds 1 and 2 incorporate a dioxopiperazine moiety with a disulfide bridge, while compound 3 contains a dioxopiperazine ring with two methylsulfanyl groups.

Bionectins A, B, and C, and verticillin D, were isolated from the liquid fermentation cultures of Bionectria byssicola F120; bionectins D and E, cyclo(L-Pro-L-Leu), dioxopiperazine, and gliocladicillins A and C were isolated from other Bionectria sp. strains.

Polyketide Glycosides (Bionectriols and TMC-151s)

A screening campaign utilising samples from a fungal extract library revealed that a Bionectria ochroleuca isolate cultured on breakfast cereal produced metabolites that blocked the in vitro formation of Candida albicans biofilms; scale-up culture afforded four known compounds (TMC-151s C–F) and three new polyketide glycosides (bionectriols B–D); all seven metabolites exhibited potent biofilm inhibition against C. albicans.

Only two references exist reporting the isolation of bionectriols from fungi, and in both cases these compounds were isolated from members of Bionectria sp. which are within the class Sordariomycetes.

Tetramic Acid Derivatives

Three tetramic acid derivatives — 1,2-dehydrovirgineone, virgineone, and virgineone aglycone — were isolated from Bionectria sp. MSX 47401 and showed notable antibacterial activity against Staphylococcus aureus and several MRSA isolates.

Peptaibols

An extract of the filamentous fungus Bionectria sp. (MSX 47401) showed both promising cytotoxic activity (greater than 90% inhibition of H460 cell growth at 20 μg/mL) and antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA); a bioactivity-directed fractionation study yielded one new peptaibol and one new tetramic acid derivative, and the fungus biosynthesised diverse secondary metabolites with mannose-derived units; five known compounds were also isolated: clonostachin, virgineone, virgineone aglycone, AGI-7, and 5,6-dihydroxybisabolol.

Bionectriamines (Induced by Co-culture)

Co-cultivation of Bionectria sp. either with Bacillus subtilis or with Streptomyces lividans resulted in the production of two new ortho-aminobenzoic acid derivatives, bionectriamines A and B, as well as two additional known compounds; none of these latter compounds were detected in axenic cultures of the fungus or the bacteria, indicating activation of silent biogenetic gene clusters through co-cultivation.

Polyketides and Other Metabolites

A variety of polyketides occur widely in the Clonostachys fungi; according to structural characteristics, these metabolites are classified into aromatic, aliphatic, and mixed biogenic polyketides; the aromatic polyketides mainly include pyranones, quinones, sorbicillinoids, and others.

Penicolinate A was induced from the endophytic fungus Bionectria sp. through bacterial co-culture and exhibited potent cytotoxic activity against the human ovarian cancer cell line A2780 with an IC50 value of 4.1 μM.

Gas chromatography–mass spectrometry analysis of crude extracts from Clonostachys rosea identified 23 compounds, including 2-piperidone, hydrocinnamic acid, phenethyl alcohol, oleic acid, tryptophol, stearic acid methyl ester, myristic acid, dodecanoic acid, and benzeneacetic acid.

Mechanisms of Biological Action

Cytotoxic Mechanisms

The cytotoxic activities of Bionectria metabolites have been characterised at the in vitro level across several compound classes. The absolute configurations of amino acids in pullularins were determined by HPLC analysis of acid hydrolysates using Marfey's method; the isolated compounds exhibited pronounced to moderate cytotoxic activity against the mouse lymphoma cell line (L5178Y) with EC50 values ranging between 0.1 and 6.7 µg/mL. The structural feature common to many of the antibacterially active piperazine-type metabolites is the disulfide bridge. Bionectins A and B incorporate a dioxopiperazine moiety with a disulfide bridge in their molecules. This epidithio motif is a hallmark of a group of fungal secondary metabolites known to exert cellular toxicity, in part through redox-active disulfide chemistry.

Antibacterial Mechanisms

Bionectins A and B exhibited antibacterial activity against S. aureus including methicillin-resistant S. aureus (MRSA) and quinolone-resistant S. aureus (QRSA), with MIC values of 10–30 µg/mL. The tetramic acid derivatives from Bionectria sp. MSX 47401 provide a second mechanistic class active against S. aureus and MRSA. Metabolites from an endophytic strain of B. ochroleuca showed a broad spectrum of antibacterial, antifungal, and anti-dermatophytic activity; minimum inhibitory concentration values of ethyl acetate extracts were in the range of 78–625 μg/mL against all test organisms, except for Pseudomonas aeruginosa (5 mg/mL).

Anti-biofilm Mechanisms

One of the challenges presented by Candida infections is that many clinical isolates produce biofilms, which can decrease these pathogens' susceptibilities to standard-of-care antibiotic therapies; inhibitors of fungal biofilm formation offer a potential solution to counteracting some of the problems associated with Candida infections. All seven bionectriol-type metabolites from B. ochroleuca exhibited potent biofilm inhibition against C. albicans SC5314, as well as synergistic antifungal activities in combination with amphotericin B.

Fibrinolytic Activity

In experiments with Bionectria ochroleuca isolates from Argentina, fibrinolytic-positive extracts were able to degrade fibrin clots in a direct plasminogen-independent way. Endophytic fungi, including Bionectria sp., are among the few reported to possess in vitro fibrinolytic activity. Fibrinolytic enzymes that act independently of plasminogen are mechanistically distinct from tissue plasminogen activators (t-PA) and represent a direct thrombolytic category.

Free Radical Scavenging

A dose-dependent free radical quenching was observed in the ethyl acetate extract of endophytic Bionectria ochroleuca NOTL33. This antioxidant activity has been documented in one published laboratory study, though the chemical identities of the specific scavenging compounds were not fully characterised.

Silent Gene Cluster Activation

None of the bacterial co-culture-induced compounds (bionectriamines A and B) were detected in axenic cultures of the fungus or of the bacteria, indicating activation of silent biogenetic gene clusters through co-cultivation with bacteria. This phenomenon — where inter-kingdom interactions unlock cryptic biosynthetic pathways — has become an important strategy in natural products discovery from Bionectria and related genera.

Scientific Evidence by Area of Biological Activity

All evidence described in this section is preclinical (in vitro or in vivo animal/cell-line-based). No human clinical trials or controlled human studies exist for Bionectria extracts or any of its isolated compounds used as dietary supplements.

Antimicrobial Activity

Evidence level: Preclinical (in vitro only).

One published study investigated the antimicrobial and free radical scavenging activity of a foliar endophytic strain of B. ochroleuca NOTL33 isolated from Nothapodytes foetida. The differences among endophytic, pathogenic, and free-living Bionectria ochroleuca were established by RNA secondary structure analysis; the metabolites showed a broad spectrum of antibacterial, antifungal, and anti-dermatophytic activity; MIC values of ethyl acetate extracts were in the range of 78–625 μg/mL against all test organisms, except for Pseudomonas aeruginosa (5 mg/mL).

The MIC and minimum bactericidal concentration of the extract were lower than those of the reference antibiotic streptomycin; the extract was bacteriostatic in nature against P. aeruginosa and bactericidal against other test strains used.

Regarding individual metabolites of defined structure: bionectins A and B exhibited antibacterial activity against S. aureus including MRSA and quinolone-resistant S. aureus (QRSA), with MIC values of 10–30 µg/mL, while bionectin C showed no antibacterial activity even at 100 µg/mL. These measurements were conducted in vitro, with no animal or human data.

Researchers obtained bionectin D from the ethyl acetate extract of endophytic Bionectria sp. Y1085, which was isolated from the plant Huperzia serrata; bionectin D exhibited significant antibacterial activity against both E. coli and S. aureus.

Anti-Candida / Anti-biofilm Activity

Evidence level: Preclinical (in vitro only).

The most detailed mechanistic study in this area used a small-scale extract of Bionectria ochroleuca identified as 99% identical to B. ochroleuca by ITS BLAST analysis grown under solid-phase conditions. Assay-guided purification yielded seven bioactive polyketide glycosides including three new metabolites, bionectriols B–D, which exhibit structural similarities to other compounds in this metabolite family, including TMC-151s, bionectriol A, and roslipin. All seven metabolites exhibited potent biofilm inhibition against C. albicans SC5314, as well as synergistic antifungal activities in combination with amphotericin B. The study was conducted entirely in vitro; there are no animal infection models or clinical data.

Cytotoxic / Anticancer Activity

Evidence level: Preclinical (in vitro cell-line and mouse lymphoma assays only).

The isolated compounds from Bionectria ochroleuca exhibited pronounced to moderate cytotoxic activity against mouse lymphoma cells (L5178Y) with EC50 values ranging between 0.1 and 6.7 µg/mL.

An extract of the filamentous fungus Bionectria sp. (MSX 47401) showed both promising cytotoxic activity — greater than 90% inhibition of H460 lung cancer cell growth at 20 μg/mL — and antibacterial activity against MRSA.

Penicolinate A, induced from the endophytic fungus Bionectria sp. through bacterial co-culture, exhibited potent cytotoxic activity against the human ovarian cancer cell line A2780 with an IC50 value of 4.1 μM.

Both pullularins A and C showed moderate cytotoxic activity against mouse lymphoma cells. All such data derive from laboratory cancer-cell-line assays. No animal tumour model data and no human oncological data for any Bionectria-derived compound appear in the published literature.

Fibrinolytic Activity

Evidence level: Preclinical (in vitro enzyme assay only).

Fibrinolytic enzyme production was evaluated in fungal specimens isolated from the subtropical Las Yungas Pedemontana forest; proteolytic and fibrinolytic activities were evaluated in freeze-thaw crude extracts from 230 fungal isolates on skimmed-milk or fibrin-agar plates. Isolates LY 4.1 and LY 4.4 showed 99.9% similarity with Bionectria ochroleuca; under submerged culture conditions, LY 4.1 and LY 4.4 were able to excrete fibrinolytic enzymes, reaching a maximum at 120 hours of cultivation of 100.2 and 107.9 U/ml. This work is enzymatic and in vitro; no cardiovascular or thrombolytic outcomes in living organisms have been evaluated.

Free Radical Scavenging / Antioxidant Activity

Evidence level: Preliminary, in vitro only.

A dose-dependent free radical quenching was observed in the ethyl acetate extract of the B. ochroleuca NOTL33 isolate; the results indicate that this isolate is a potential source of antimicrobial agents and could be used as an effective biofumigant. The specific chemical species responsible for the antioxidant activity were not identified in this study, and no structured comparison with established antioxidant standards was reported beyond the observation of dose-dependence.

Body Systems and Health Areas Associated with Bionectria Research

Based exclusively on peer-reviewed in vitro and preclinical studies, the following body systems and health areas are relevant to Bionectria secondary metabolite research. All associations are purely laboratory-level and preclinical:

• Infectious disease and immunology: The fungal genus Bionectria produces metabolites exhibiting a broad range of antibacterial, antifungal, and anti-dermatophytic activity. Compounds active against MRSA, gram-positive and gram-negative bacteria, and Candida albicans biofilms have been characterised.
• Oncology (experimental): Many Bionectria / Clonostachys compounds exhibit cytotoxic, antimicrobial, antileishmanial, and antimalarial activities. Cytotoxicity data against mouse lymphoma lines, H460 lung cancer cells, and A2780 ovarian cancer cells have been published.
• Haematology / thrombosis (experimental): Bionectria ochroleuca has been documented as a potential source of fibrinolytic enzymes capable of direct, plasminogen-independent fibrin degradation in vitro.
• Antiparasitic activity (exploratory): Antileishmanial and antimalarial activities have been reported for metabolites from the Clonostachys/Bionectria genus.
• Agricultural and environmental biology: Clonostachys species (teleomorph: Bionectria) produce enzymes and bioactive metabolites with antimicrobial, antifungal, nematocidal, anticancer, and antioxidant properties; they can also degrade plastic waste and remove hydrocarbons from crude oil-contaminated sites when functioning as endophytes.

Dosage Forms and Preparations Used in Research

No standardised dietary supplement dosage, formulation, or delivery form for Bionectria exists. The following describes only the laboratory-scale extraction and culture methods reported in peer-reviewed studies:

• The crude ethyl acetate extract of Bionectria ochroleuca cultured on solid rice medium was taken to dryness and partitioned between n-hexane and 90% methanol for further fractionation.
• For biofilm inhibition studies, B. ochroleuca was inoculated onto breakfast cereal in Erlenmeyer flasks and mycobags; cultures were incubated at 25°C under identical lighting for 4 weeks; the secondary metabolites from both sets of cultures were extracted with ethyl acetate for chemical analysis and biological testing.
• The bionectins were isolated from the mycelium of liquid fermentation cultures of Bionectra byssicola F120.
• Minimum inhibitory concentrations (MICs) for antibacterial activity were reported as: MIC values of 10–30 µg/mL for bionectins A and B against MRSA and QRSA.
• MIC values for crude ethyl acetate extracts of B. ochroleuca NOTL33 were in the range of 78–625 μg/mL against test organisms, except for P. aeruginosa (5 mg/mL).
• Cytotoxicity for pullularins from B. ochroleuca: EC50 values of 0.1 to 6.7 µg/mL against mouse lymphoma cells (L5178Y).
• For penicolinate A: IC50 value of 4.1 μM against the human ovarian cancer cell line A2780.
• Fibrinolytic enzyme production in submerged culture reached a maximum at 120 hours of cultivation of 100.2 and 107.9 U/ml for isolates LY 4.1 and LY 4.4, respectively.

Safety Considerations

No formal toxicology studies, safety assessments, acceptable daily intake values, or adverse event data for human consumption of any Bionectria extract or derivative have been published in the peer-reviewed literature. The following factual observations from the research literature are directly relevant to safety:

• Mycotoxin-producing relatives: Bionectria belongs to the order Hypocreales, which includes well-characterised mycotoxin-producing genera. Several bioactive metabolites isolated from Bionectria and its anamorphic counterpart Clonostachys rosea have demonstrated cytotoxicity in cell lines, meaning the same secondary metabolites that are of interest pharmacologically may also pose toxicological risks at inappropriate doses.
• Epidithiodioxopiperazine class toxicity: The bionectins belong to the epidithiodioxopiperazine (ETP) class of fungal secondary metabolites. ETPs as a class are known for their potent cytotoxic and immunosuppressive properties, reflecting both their potential pharmacological utility and their inherent toxicological hazard.
• Plant pathogen status: Bionectria ochroleuca is documented as a plant pathogen that causes seed rot in oilseed rape.
• Insecticidal metabolites: Crude extracts of Clonostachys rosea at a concentration of 7.5 μg/mL exhibited high toxicity; two hours post-treatment, larval mortality reached 65%; contact toxicity was more lethal than oral exposure; a total of 23 compounds were identified from the crude extract, of which nine exhibited toxicity.
• Ongoing agricultural safety surveillance: There are challenges and limitations, including the continuous surveillance of the safety of Clonostachys species on plants, the establishment of commercial applications, formulation viability, and variability due to field conditions; these issues will have to be addressed.
• No regulatory approval: No regulatory body (FDA, EMA, EFSA, TGA) has approved any Bionectria-derived ingredient for human consumption. The genus is absent from all official dietary supplement ingredient registries, GRAS (Generally Recognized As Safe) lists, and novel food catalogues reviewed in this research.

State of Evidence: Summary Assessment

The overall body of evidence for Bionectria as a health-relevant natural product is strictly preclinical. Clonostachys (teleomorph: Bionectria) fungi are well known to produce a variety of secondary metabolites with various biological activities with potential pharmaceutical and agrochemical applications; at least 229 secondary metabolites have been catalogued. However, the transition from in vitro bioactivity data to validated therapeutic or dietary supplement use requires animal safety studies, pharmacokinetic characterisation, toxicology data, and ultimately randomised controlled human trials — none of which exist for Bionectria-derived preparations. The published evidence base consists entirely of:

• Chemical isolation and structural characterisation studies
• In vitro cell-line cytotoxicity and antibacterial assays
• In vitro enzyme (fibrinolytic) activity assays
• In vitro anti-biofilm assays
• Observational ecological and taxonomic studies

This represents an early discovery stage of research. The gap between these findings and any established role in human nutrition or health intervention is substantial and has not been bridged by any published evidence as of the current literature.

References

• Ebrahim W et al. (2012). Pullularins E and F, Two New Peptides from the Endophytic Fungus Bionectria ochroleuca Isolated from the Mangrove Plant Sonneratia caseolaris. Marine Drugs 10(5):1081–1091. PMC3397455.
• Raja HA et al. (2014). Polyketide Glycosides from Bionectria ochroleuca Inhibit Candida albicans Biofilm Formation. Journal of Natural Products. PMC4208675.
• Pannecouque J et al. (2013). Peptaibols, Tetramic Acid Derivatives, Isocoumarins and Sesquiterpenes from a Bionectria sp. (MSX 47401). PMC3736820.
• Toghueo RMK et al. (2013). Bionectria ochroleuca NOTL33 — an endophytic fungus from Nothapodytes foetida producing antimicrobial and free radical scavenging metabolites. Annals of Microbiology. BioMed Central.
• Li P et al. (2020). Metabolites from Clonostachys Fungi and Their Biological Activities. Journal of Fungi 6(4):229. PMC7712584.
• Zheng CJ et al. (2006). Bionectins A–C, Epidithiodioxopiperazines with Anti-MRSA Activity, from Bionectra byssicola F120. Journal of Natural Products 69(12):1816–1819. PubMed PMID 17190469.
• Kaaniche F et al. (2017). Induction of new metabolites from the endophytic fungus Bionectria sp. through bacterial co-culture. Fitoterapia. ScienceDirect.
• GBIF Backbone Taxonomy. Bionectria ochroleuca (Schwein.) Schroers & Samuels. Global Biodiversity Information Facility.
• Gräfenhan T et al. (2001). Molecular studies of the Bionectriaceae using large subunit rDNA sequences. Mycologia 93(1).
• Schroers HJ et al. (1999). Classification of the mycoparasite Gliocladium roseum in Clonostachys as C. rosea, its relationship to Bionectria ochroleuca. Mycologia 91(2).
• Rossman AY et al. (2013). Genera in Bionectriaceae, Hypocreaceae, and Nectriaceae (Hypocreales) proposed for acceptance or rejection. IMA Fungus 4(1).
• Schroers HJ (2001). A monograph of Bionectria (Ascomycota, Hypocreales, Bionectriaceae) and its Clonostachys anamorph. Studies in Mycology 46. ResearchGate.
• Rovati JI et al. (2009). A novel source of fibrinolytic activity: Bionectria sp., an unconventional enzyme-producing fungus isolated from Las Yungas rainforest (Tucumán, Argentina). World Journal of Microbiology and Biotechnology.
• Kaul S et al. (2016). Potential fibrinolytic activity of an endophytic Lasiodiplodia pseudotheobromae species. 3 Biotech.
• Lim CS et al. (2022). Enhancing the Discovery of Bioactive Secondary Metabolites From Fungal Endophytes Using Chemical Elicitation and Variation of Fermentation Media. Frontiers in Microbiology 13:898976.
• Jiang Y et al. (2025). Analysis of Toxic Components in Secondary Metabolites of Entomopathogenic Fungi Clonostachys rosea from Cephalcia chuxiongica. Microorganisms 13(10):2289.
• The Genus Clonostachys (Bionectria) as a Potential Tool Against Agricultural Pest and Other Biotechnological Applications: A Review. Microbiology Research 16(4):86 (2025).
• Raja HA et al. (2014). Polyketide glycosides from Bionectria ochroleuca inhibit Candida albicans biofilm formation. PubMed PMID 25302529.
• Cytotoxic epipolythiodioxopiperazine alkaloids from filamentous fungi of the Bionectriaceae. The Journal of Antibiotics. Nature Publishing Group.